Abuse Liability of Four Modern Oral Nicotine Products
- Sponsor
- RAI Services Company
- Study ID
- NCT07685795
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Smoking
- Smoking Behaviors
- Tobacco Smoking
- Tobacco Use
Eligibility Criteria
- Sex
- ALL
- Age
- 21 Years - 60 Years
- Healthy Volunteers
- Accepted
Interventions
- Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette — OTHERUsual Brand (UB) filtered, menthol or non-menthol combustible cigarette
- Wintergreen (fleece A), 12 mg nicotine — OTHERWintergreen (fleece A), 12 mg nicotine
- Wintergreen (fleece A), 9 mg nicotine — OTHERWintergreen (fleece A), 9 mg nicotine
- Wintergreen (fleece B), 9 mg Nicotine — OTHERWintergreen (fleece B), 9 mg Nicotine
- Watermelon Mint (fleece A), 9 mg Nicotine — OTHERWatermelon Mint (fleece A), 9 mg Nicotine
- UB moist snuff (UB MST), either loose or portioned (pouched). — OTHERUB moist snuff (UB MST), either loose or portioned (pouched).
Study Details
This is a single-site, open-label, randomized, 6-way crossover study designed to evaluate elements of abuse liability (AL) including subjective effects, physiological measures (pharmacodynamics \[PD\]), and plasma nicotine uptake (pharmacokinetics \[PK\]) during controlled monitored use and following ad libitum use of the study investigational products (IPs) by generally healthy smokers who are also users of smokeless tobacco.
Key Dates
- First listed
- Jul 6, 2026
- Start date
- Jul 15, 2026
- Status verified
- Jun 2026
- Primary completion
- Sep 15, 2026
- Completion
- Jan 31, 2027
Study Design
- Enrollment
- 50 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- OTHER
Arms
- Experimental: Product usage order ASDECBSubjects will use each of the 6 products during an evaluation period, followed by a 1 hour Test Session and a 7 hour ad lib session
- Experimental: Product usage order BAESDCSubjects will use each of the 6 products during an evaluation period, followed by a 1 hour Test Session and a 7 hour ad lib session
- Experimental: Product usage order CBSAEDSubjects will use each of the 6 products during an evaluation period, followed by a 1 hour Test Session and a 7 hour ad lib session
- Experimental: Product usage order DCABSESubjects will use each of the 6 products during an evaluation period, followed by a 1 hour Test Session and a 7 hour ad lib session
- Experimental: Product usage order EDBCASSubjects will use each of the 6 products during an evaluation period, followed by a 1 hour Test Session and a 7 hour ad lib session
- Experimental: Product usage order SECDBASubjects will use each of the 6 products during an evaluation period, followed by a 1 hour Test Session and a 7 hour ad lib session
Primary Outcome Measure
AUECPL 5-60 [ Time Frame: 5 minutes to 60 minutes ]
Central Contacts
- John Darnell3367410386
- Kristen Prevette3367411873
Related Studies
- Collection of Airway, Blood and/or Urine Specimens From Subjects for Research StudiesRecruiting · Weill Medical College of Cornell University · New York, New York
- Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as CorrelatesPHASE4 · Recruiting · Corporal Michael J. Crescenz VA Medical Center · Philadelphia, Pennsylvania
- Effects of a Specific Substance in SmokersRecruiting · Oregon Health and Science University · Portland, Oregon
- Antibiotic Prophylaxis in High-Risk Arthroplasty PatientsPHASE4 · Enrolling By Invitation · Mayo Clinic · Iowa City, Iowa